Santaris' first-half losses narrow
This article was originally published in Scrip
Executive Summary
Santaris Pharma's second-quarter net loss decreased by 28% to DKK21.6 million ($4 million) following a significant reduction in R&D and administrative costs compared with the same period in 2008.